Literature DB >> 31691152

BET bromodomain inhibition suppresses adipogenesis in mice.

Qiong Duan1,2, Pei Wu3, Zhenzhen Liu3, Fan Xia4,5, Lingyan Zhu3,6, Zeqi Zheng4,5, Tianlun Yang7, Jun Qi8,9.   

Abstract

PURPOSE: We recently reported that inhibition of BET bromodomain suppresses adipogenesis in vitro. In the present study we aimed to address whether BET bromodomain inhibition can suppress adipogenesis in vivo.
METHODS: Brd4fl/fl mice were crossed with B6.Cg-Tg(Fabp4-cre)1Rev/J mice to generate Brd4fl/+/Fabp4-cre mice. We used high fat diet (HFD, 45% fat) mice treated with vehicle (DMSO) or JQ1 (intraperitoneal, IP injection, 50 mg/kg/day), respectively, for 6 weeks. Body weight was measured once a week. Dual-energy X-ray absorptiometry was determined and brown adipose tissue was harvested at the end of the experiment.
RESULTS: Partial deletion of Brd4 leads to the lower body weight. JQ1 treatment further confirmed that BET bromodomain inhibition suppresses body weight gain and decreases white adipose depots compared with the control mice. In addition, JQ1 treatment reduces the size of brown adipose tissue and impairs its thermogenesis.
CONCLUSIONS: BET bromodomain inhibition suppresses adipogenesis in the mice.

Entities:  

Keywords:  Adipogenesis; BET bromodomain; Epigenetics; JQ1

Mesh:

Substances:

Year:  2019        PMID: 31691152     DOI: 10.1007/s12020-019-02115-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  11 in total

Review 1.  Adipocyte differentiation from the inside out.

Authors:  Evan D Rosen; Ormond A MacDougald
Journal:  Nat Rev Mol Cell Biol       Date:  2006-12       Impact factor: 94.444

Review 2.  PPARγ and the global map of adipogenesis and beyond.

Authors:  Martina I Lefterova; Anders K Haakonsson; Mitchell A Lazar; Susanne Mandrup
Journal:  Trends Endocrinol Metab       Date:  2014-04-29       Impact factor: 12.015

Review 3.  Central nervous system control of food intake and body weight.

Authors:  G J Morton; D E Cummings; D G Baskin; G S Barsh; M W Schwartz
Journal:  Nature       Date:  2006-09-21       Impact factor: 49.962

4.  Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4.

Authors:  Denis Houzelstein; Simon L Bullock; Denise E Lynch; Elena F Grigorieva; Valerie A Wilson; Rosa S P Beddington
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

5.  18F-FDG PET/CT monitoring of β3 agonist-stimulated brown adipocyte recruitment in white adipose tissue.

Authors:  Jin Won Park; Kyung-Ho Jung; Jin Hee Lee; Cung Hoa Thien Quach; Seung-Hwan Moon; Young Seok Cho; Kyung-Han Lee
Journal:  J Nucl Med       Date:  2014-12-18       Impact factor: 10.057

6.  Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin.

Authors:  Miguel López; Ricardo Lage; Asish K Saha; Diego Pérez-Tilve; María J Vázquez; Luis Varela; Susana Sangiao-Alvarellos; Sulay Tovar; Kawtar Raghay; Sergio Rodríguez-Cuenca; Rosangela M Deoliveira; Tamara Castañeda; Rakesh Datta; Jesse Z Dong; Michael Culler; Mark W Sleeman; Clara V Alvarez; Rosalía Gallego; Christopher J Lelliott; David Carling; Matthias H Tschöp; Carlos Diéguez; Antonio Vidal-Puig
Journal:  Cell Metab       Date:  2008-05       Impact factor: 27.287

7.  Brd4 binds to active enhancers to control cell identity gene induction in adipogenesis and myogenesis.

Authors:  Ji-Eun Lee; Young-Kwon Park; Sarah Park; Younghoon Jang; Nicholas Waring; Anup Dey; Keiko Ozato; Binbin Lai; Weiqun Peng; Kai Ge
Journal:  Nat Commun       Date:  2017-12-20       Impact factor: 14.919

8.  BET bromodomain proteins regulate enhancer function during adipogenesis.

Authors:  Jonathan D Brown; Zachary B Feldman; Sean P Doherty; Jaime M Reyes; Peter B Rahl; Charles Y Lin; Quanhu Sheng; Qiong Duan; Alexander J Federation; Andrew L Kung; Saptarsi M Haldar; Richard A Young; Jorge Plutzky; James E Bradner
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-14       Impact factor: 11.205

9.  Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis.

Authors:  Xiaoyan Tang; Ruoqi Peng; Jonathan E Phillips; Jeremy Deguzman; Yonglin Ren; Subramanium Apparsundaram; Qi Luo; Carla M Bauer; Maria E Fuentes; Julie A DeMartino; Gaurav Tyagi; Rosario Garrido; Cory M Hogaboam; Christopher P Denton; Alan M Holmes; Christopher Kitson; Christopher S Stevenson; David C Budd
Journal:  Am J Pathol       Date:  2013-06-10       Impact factor: 4.307

10.  Selective inhibition of BET bromodomains.

Authors:  Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal:  Nature       Date:  2010-09-24       Impact factor: 49.962

View more
  4 in total

1.  Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis.

Authors:  Rong Fu; Shi-Jia Zu; Yan-Jun Liu; Jia-Cheng Li; Wen-Zhen Dang; Li-Ping Liao; Li-Ping Liu; Pan-Yu Chen; He-Ming Huang; Kang-Hui Wu; Bing Zhou; Qin Pan; Cheng Luo; Yuan-Yuan Zhang; Guang-Ming Li
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

2.  PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc.

Authors:  Zhiheng Li; Su Lin Lim; Yanfang Tao; Xiaolu Li; Yi Xie; Chun Yang; Zimu Zhang; You Jiang; Xianbing Zhang; Xu Cao; Hairong Wang; Guanghui Qian; Yi Wu; Mei Li; Fang Fang; Ying Liu; Mingcui Fu; Xin Ding; Zhenghong Zhu; Haitao Lv; Jun Lu; Sheng Xiao; Shaoyan Hu; Jian Pan
Journal:  Front Oncol       Date:  2020-11-26       Impact factor: 6.244

3.  ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways.

Authors:  Xinmei Liao; Xiaoqing Qian; Zimu Zhang; Yanfang Tao; Zhiheng Li; Qian Zhang; Hui Liang; Xiaolu Li; Yi Xie; Ran Zhuo; Yanling Chen; You Jiang; Haibo Cao; Jiaqi Niu; Cuili Xue; Jian Ni; Jian Pan; Daxiang Cui
Journal:  Front Oncol       Date:  2021-10-18       Impact factor: 6.244

Review 4.  Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases.

Authors:  Dayu Wu; Qiong Duan
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.